Dr. Ying Bo, CEO of AbogenTo Attend Drug Delivery Science Symposium in Singapore and Share Research Findings
Dr. Ying Bo, Founder, Chairman and CEO of Abogen Biosciences, will attend the event hosted by the Controlled Release Society in Singapore on February 20 this year."CRS Singapore 2025 Symposium: Connecting Global Delivery Science"（“CRSingapore 2025: Connecting Continents in Delivery Science”）。As a keynote speaker, he will join global scientists and clinical experts to discuss the latest advances in delivery science and introduce the industry perspective on mRNA therapeutics and vaccines.Dr. Ying Bo is the founder, chairman, and chief executive officer of Abogen Biosciences. Since its establishment in 2019, Abogen has rapidly grown into a leading company in China's mRNA drug therapy field, building a proprietary technology platform for mRNA and nanocarrier delivery systems, with a focus on treating infectious diseases, autoimmune disorders, and cancer.
Dr. Ying Bo graduated from Fudan University with a bachelor's and master’s degree, and later obtained his Ph.D. in Pharmaceutics from Northeastern University in Boston, USA. He is the inventor of multiple overseas patents and has published several research papers in top international academic journals such as Cell and The Lancet.Delivery technology is considered the "last mile" of drug development, attracting significant attention, especially for mRNA drugs.In the future, delivery technologies will continue to innovate and make breakthroughs in improving delivery efficiency and achieving non-liver targeting, which is expected to further expand the application scope of RNA therapies and unlock broader prospects.The CRS Singapore Symposium with the theme of Delivery Science wasControlled Release Society (CRS), National University of Singapore (NUS), and National University Health System (NUHS)Co-organized, bringing together industry experts, scholars, and corporate representatives from around the globe to exchange the latest scientific discoveries and technological advancements. The conference aims to promote cross-border collaboration, building a technological bridge connecting continents, and jointly creating a more efficient and closely cooperative future in the field of drug delivery science.Introduction to the Sharing Session by Abogen's CEOTime:February 20, 2025 14:45-15:10Subject：mRNIndustrial Perspective of mRNA-Based Therapeutics and VaccinesControlled Release Society (CRS)The Controlled Release Society (CRS) is a high-impact international organization in the field of pharmaceutics, focusing on the research and application of drug, cosmetic, fragrance, and other active ingredient delivery. Through fundamental delivery science research, development, regulation, and clinical translation, CRS members are committed to advancing the future of drug delivery science. The CRS has hosted numerous symposia covering various fields such as mRNA therapy, oral delivery technology, innovations in drug delivery and diagnostics, women's health, and pediatric medications.For more information about the conference, please visit the official website:https://www.controlledreleasesociety.org/events/crsingapore-2025-connecting-continents-delivery-science
About Us
Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company focusing on the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary intellectual property rights over its mRNA and nanodelivery technology platforms. It is one of the few mRNA drug research and development enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline, spanning multiple fields including infectious disease prevention and control (such as mRNA COVID-19 vaccines), tumor immunology, protein replacement therapy, and more.
